Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.155 USD | -2.12% | -12.50% | +100.87% |
Apr. 22 | Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating | MT |
Apr. 22 | Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+100.87% | 304M | |
+0.82% | 43.84B | |
+4.60% | 41.68B | |
+45.32% | 41.25B | |
-10.92% | 27.04B | |
+7.26% | 25.53B | |
-25.68% | 18.18B | |
-3.91% | 12.29B | |
+25.15% | 12.29B | |
+6.67% | 11.15B |
- Stock Market
- Equities
- OCGN Stock
- News Ocugen, Inc.
- Ocugen Says US FDA Issued Clinical Hold on its Investigational New Drug Application for COVID-19 Vaccine Candidate